![]() She is currently a Deputy Editor for Immunology and Cell Biology. A/Prof Lawlor is also actively engaged with industry, acting as a scientific consultant for a number of companies, including CSL, and is an inventor on a patent for an anti-inflammatory therapy, now under licence and in phase I clinical trials. This work has resulted in numerous publications in prestigious journals, including Nature, Nature Immunology, Nature Microbiology, Immunity, Cell, Nature Communications, Cell Reports, EMBO Reports and PNAS. Her recent work has transformed our understanding of programmed cell death in the context of inflammation, by revealing how distinct cell death pathways can activate pattern recognition receptors, called inflammasomes, to promote inflammation. Since she was recruited to her current position in 2018, A/Prof Lawlor has been awarded an ARC Future Fellowship (2020-23) and NHMRC funding (CIC 2018-20, CIA 2019-21, CIA 2020-22). During this time, she established expertise in the molecular and cellular dissection of inflammatory signalling pathways, and the translation of these findings in vivo using models of autoimmune, inflammatory and infectious diseases. After being awarded an NHMRC CJ Martin Overseas Biomedical Fellowship, she completed postdoctoral research at the Cambridge Institute for Medical Research, University of Cambridge, UK and the Walter and Eliza Hall Institute, most recently in the laboratory of Dr James Vince. A/Prof Lawlor received her PhD in Medical Biology in 2004 at the Walter and Eliza Hall Institute of Medical Research and The University of Melbourne. ![]() Role: Research Group Head Group: Cell Death and Inflammatory SignallingĪssociate Professor Kate Lawlor heads the Cell Death and Inflammatory Signalling Group within the Centre for Innate Immunity and Infectious Diseases at the Hudson Institute. ![]()
0 Comments
Leave a Reply. |